Excipients Step into the Spotlight - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Excipients Step into the Spotlight
Industry and regulatory experts discuss excipient testing, regulatory expectations, supply-chain challenges, and pricing in this Speakers Roundtable. This article contains bonus online material and podcasts.


Pharmaceutical Technology
Volume 6, Issue 34, pp. 38-42

PharmTech: How is industry using excipients today compared with 10 years ago?


FDA's Rosa Motta. (PHOTO: COURTESY EXCIPIENTFEST)
Busch: The biggest change has been the improved understanding of the role excipients play in the final performance of the API. Excipients have been defined as an inactive substance used as a carrier for the active ingredients of a medication. This is, in fact, the first sentence when one looks up 'excipient' in Wikipedia (May 21, 2010). IPEC defines excipients as any substance other than the active drug or product that is included in the manufacturing process or is contained in a finished pharmaceutical dosage form. Today, it is well understood that excipients provide a range of functionality—from process aids for lubricity, flowability, and compressibility to finished dosage-form functionality aids, which may improve the availability or control the dissolution rate of an API. The US Pharmacopeia-National Formulary (USP-NF) includes extensive categorizations of excipients.

With the advent of FDA's QbD initiative, drug manufacturers are being asked to provide proof of their understanding of the role each excipient plays in their finished formulation. This requires the drug manufacturer to run a design of experiments (DOE) to understand the role that each ingredient in the formulation plays in the final dosage-form functionality. In the ideal case, the manufacturer can develop a design space to predict the finished dosage-form performance based on properties of the individual formulation components. Because there is inherent variability in any raw material, the key challenge is to develop robust formulations that will be able to use the excipient within its variability. Can a manufacturer use any excipient that meets its specification limits? If so, the manufacturer has a robust formulation.

Excipient variability is compounded, however, when purchasing material from different suppliers, who may use different processes and unit operations to produce the excipient. Two excipients may not be interchangeable, and thus, it is important to understand the differences and how they affect processing and final dosage form.

To correct for inherent variability, both formulation flexibility and process flexibility are needed, the degree of flexibility being dependent upon limits determined during the design space development. Excipient variability is compounded when purchasing material from different suppliers, who may use different processes and unit operations to produce the excipient. Two excipients may not be interchangeable, and thus, an understanding of the differences and how they affect the processing and final dosage form must be achieved.

PharmTech: Why is industry's understanding and control of excipients important to FDA?

Motta: Excipients generally comprise a significant portion of a dosage form and can potentially compromise drug product quality if their quality is not adequately controlled. A single batch of an excipient can be used to manufacture many batches of drug products. Thus, an excipient manufactured or held under subpar conditions can cause a large number of drugs to be adulterated, potentially putting patients at risk or resulting in a shortage of a medically necessary drug. Although excipients are not pharmacologically active, many excipients play a key role in drug bioavailability. Even excipients that are less prominent in their functionality have quality attributes that, if not adequately controlled, might compromise the quality, stability, or performance of the drug product. In the worst case—demonstrated by recurring events in which diethylene glycol (DEG) was added to an excipient to increase its market value—when excipients are not controlled, the result can be a widespread outbreak of serious adverse events.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here